Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Terminated 4Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Breast 1

Conditions

Recurrence 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has results × ridaforolimus × Clear all
NCT01169532 2021-02-21

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Fox Chase Cancer Center

Phase 1 Completed
16 enrolled 7 charts
Lymphoid

Lymphoma

NCT00874731 2019-05-06

MK-8669-037

Merck Sharp & Dohme LLC

Phase 1 Completed
23 enrolled 14 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01380184 2019-04-19

MK-8669-059

Merck Sharp & Dohme LLC

Phase 1 Completed
15 enrolled 15 charts

Neoplasms, Recurrence

NCT01605396 2019-03-25

MK-8669-064

Merck Sharp & Dohme LLC

Phase 2 Completed
80 enrolled 13 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡